BridgeMD
Compares treatment options for Melasma
Official title Injectable Platelet-Rich Fibrin Versus Intradermal Tranexamic Acid for Melasma
ClinicalTrials.gov ID: NCT07540702
What this study is testing
What is Injectable Platelet-Rich Fibrin?
Injectable Platelet-Rich Fibrin is an investigational medicine, given as an infusion into a vein, being studied as a potential treatment for melasma.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Melasma is a chronic acquired hyperpigmentation disorder that commonly affects the face and has a significant impact on quality of life. Available treatments may improve pigmentation, but relapse is common and response can be variable.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 50, women only
You may be able to join if
- Clinical diagnosis of bilateral symmetrical facial melasma (epidermal or mixed type)
- Female participants aged 18 to 50 years
- Fitzpatrick skin types III to IV
- Mild to moderate facial melasma
- No melasma-specific treatment within the previous 4 weeks
You likely can't join if
- Pregnancy or lactation
- Bleeding or coagulation disorders
- Use of anticoagulants, nonsteroidal anti-inflammatory drugs (NSAIDs), or hormonal contraception
- Active skin infection or facial inflammation
- History of keloids or Koebner-prone conditions, such as psoriasis or vitiligo
- Uncontrolled systemic disease, such as diabetes mellitus or autoimmune disease
See the full eligibility criteria
- Clinical diagnosis of bilateral symmetrical facial melasma (epidermal or mixed type)
- Female participants aged 18 to 50 years
- Fitzpatrick skin types III to IV
- Mild to moderate facial melasma
- No melasma-specific treatment within the previous 4 weeks
- No facial procedures, including peeling, laser resurfacing, or microneedling, within the previous 3 months
- Willing and able to provide written informed consent and comply with study procedures
- Pregnancy or lactation
- Bleeding or coagulation disorders
- Use of anticoagulants, nonsteroidal anti-inflammatory drugs (NSAIDs), or hormonal contraception
- Active skin infection or facial inflammation
- History of keloids or Koebner-prone conditions, such as psoriasis or vitiligo
- Uncontrolled systemic disease, such as diabetes mellitus or autoimmune disease
The study team makes the final eligibility decision.
Where it's taking place
- Cairo, Cairo Governorate, Egypt
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling female, 18 years to 50 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Cairo, Cairo Governorate, Egypt. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.